Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
AssigneeZogenix International Limited
InventorsStephen J. Farr, Brooks Boyd
Life of this patent
Estimating the term…
Abstract
Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
Claims10
A method of reducing or ameliorating seizures in a patient, comprising:
- administering fenfluramine;
- and
- administering cannabidiol thereby modulating down formation of norfenfluramine, and resulting in higher levels of fenfluramine.
A method of reducing or ameliorating seizures in a patient diagnosed with a form of refractory epilepsy, comprising:
- administering a liquid formulation of fenfluramine to the patient in an amount in the range of 0.2 mg/kg/day to 0.8 mg/kg/day;
- and
- administering cannabidiol in a liquid formulation in an amount of 0.5 mg/kg/day to 25 mg/kg/day thereby modulating down formation of norfenfluramine, and resulting in higher levels of fenfluramine.
A method of reducing or ameliorating seizures in a patient diagnosed with a form of refractory epilepsy, comprising:
- administering a liquid formulation of fenfluramine to the patient in an amount which is 30% less than an effective amount in the range of 0.2 mg/kg/day to 0.8 mg/kg/day, due to co-administration of cannabidiol in a liquid formulation in an amount of 0.5 mg/kg/day to 25 mg/kg/day thereby modulating down formation of norfenfluramine, and resulting in higher levels of fenfluramine.
A method of reducing or ameliorating seizures patient diagnosed with Dravet syndrome, comprising:
- administering a liquid formulation of fenfluramine to the patient in an amount in the range of 0.2 mg/kg/day to 0.8 mg/kg/day;
- and
- administering cannabidiol in a liquid formulation in an amount of 0.5 mg/kg/day to 25 mg/kg/day thereby modulating down formation of norfenfluramine, and resulting in higher levels of fenfluramine.
A method of reducing or ameliorating seizures in a patient diagnosed with Dravet syndrome, comprising:
- administering a liquid formulation of fenfluramine to the patient in an amount which is 40% less than an effective amount in the range of 0.2 mg/kg/day to 0.8 mg/kg/day, due to co-administration of cannabidiol in a liquid formulation in an amount of 0.5 mg/kg/day to 25 mg/kg/day thereby modulating down formation of norfenfluramine, and resulting in higher levels of fenfluramine.
Dependencies are inferred from the claim text.